GlassScriptPhysician profile
Noe R Olvera
NPI 1417006784
$4,196.86
in general payments reported to CMS, 2019-2025
27 companies · $1,257 in 2025
The $1,257 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $978 · 2020: $454 · 2021: $27.03 · 2022: $129 · 2023: $371 · 2024: $982 · 2025: $1,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,361 · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,361.18 |
| Education | $248.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $848.32 | 2019-2025 | Tavneos, Otezla, Evenity |
| Janssen Biotech, INC. | $493.57 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $258.06 | 2019-2025 | Taltz |
| Ucb, INC. | $253.65 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $248.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $244.70 | 2023-2025 | Saphnelo |
| Genzyme Corporation | $224.56 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $180.17 | 2019-2024 | Orencia |
| Sanofi-Aventis U.S. LLC | $178.40 | 2019-2020 | |
| Abbvie INC. | $176.45 | 2019-2025 | |
| Fresenius Kabi USA, LLC | $165.97 | 2023-2025 | Idacio, Tyenne |
| Pfizer INC. | $148.32 | 2019-2024 | |
| Ani Pharmaceuticals, INC. | $119.38 | 2024-2025 | Purified Cortrophin Gel |
| Celgene Corporation | $116.99 | 2019 | |
| Hikma Pharmaceuticals USA | $112.80 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $87.47 | 2019-2025 | Gazyva, Actemra |
| Sobi, INC | $70.08 | 2024-2025 | |
| Medtronic USA, INC. | $69.13 | 2019 | |
| Glaxosmithkline, LLC. | $42.63 | 2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.10 | 2025 | |
| Octapharma USA, INC. | $24.10 | 2023 | Octagam Immune Globulin (Human) |
| Radius Health, INC. | $23.38 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2023 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $17.18 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $15.00 | 2023 | Reditrex |
| Mallinckrodt Hospital Products INC. | $13.99 | 2024 | Acthar |
| Horizon Therapeutics Plc | $13.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noe Olvera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.